CD8A and neoplasm: Moreover, genetic deletion or pharmacological inhibition of PCSK9 in tumor cells can enhance the antitumor activity of CD8<sup>+</sup> T cells by alleviating the suppressive effect on CD8<sup>+</sup> T cells and consequently inhibit tumor progression.